Aisel Health has raised €1.7 million in pre-seed funding to expand its purpose-built operating system for psychiatry and support the Danish HealthTech company’s entry into the UK market. The round was led by Caesar Ventures, with participation from Nordic Web Ventures, LifeX and Angel Invest. Existing investors Rockstart and EIFO also participated.
Aisel is developing an operating system specifically for psychiatric and mental health care rather than applying generalized healthcare software to psychiatric workflows.
The company believes one of the major challenges facing psychiatrists is no longer simply producing clinical documentation, particularly as AI-powered scribes increasingly automate note-taking.
Instead, Aisel sees the larger problem shifting toward finding, organizing, and interpreting the growing volume of information already contained within patient records.
Its research project, The Documentation Minute, found that psychiatrists spend substantially more time gathering evidence than writing the final clinical note.
That process can include locating information across referrals, historical notes and multiple clinical systems before a clinician can properly assess a patient.
Aisel argues that this fragmentation often leaves information technically available but too difficult or time-consuming for clinicians to retrieve during care.
The company’s platform consolidates that clinical context and surfaces information when it becomes relevant.
Aisel can process consultation recordings, existing documents and information provided directly by patients.
It then turns those sources into structured and contextual insights tailored to the clinician’s current task.
The platform is intended to support psychiatrists before, during and after patient consultations.
Aisel’s broader thesis is that AI’s value in psychiatry will increasingly come from helping clinicians understand the complete history surrounding a patient rather than simply generating documentation faster.
The company plans to use the pre-seed financing to expand its clinical and engineering teams.
Capital will also support Aisel’s entry into the UK, where the company is working to convert an active commercial pipeline among private psychiatry providers.
Aisel plans to pursue a Seed financing round after making further progress on that expansion.
Ultimately, the company wants to reduce administrative and information-retrieval burdens so psychiatrists can spend more time on clinical decision-making and potentially help healthcare providers address long patient waiting lists.
KEY QUOTES:
“Psychiatry doesn’t need more generic technology bolted onto an already overburdened workflow. It needs a product built around the realities of psychiatric care, where clinicians bring judgment, empathy, and years of trained intuition, and the technology brings the speed, structure, and ability to hold together every detail about every patient, in a way no human memory can.”
Augusta Klingsten Peytz, Co-Founder And CEO Of Aisel Health
“AI scribes work, they write notes faster, and that’s great for immediate burnout. But that’s not what’s keeping waiting lists long. Make notes cheaper to produce, and you just make that information harder to find when a clinician needs it. We still have yet to overcome the human limitation of understanding everything that was ever written about every patient ever treated, that’s the problem we built Aisel to solve: giving clinicians exactly what they need, when and how they need it.”
Christian Houen, Co-Founder And CPO Of Aisel Health
“Few problems in healthcare are as large or as overlooked as psychiatry’s, and few founders are as passionate about solving it the way Augusta and Christian are. We’re proud to lead this round, and look forward to supporting them to deliver the next generation of technology for psychiatry.”
Carolin Gabor, Managing Partner And GP At Caesar Ventures
“We look for European quality and diligence and American ambitions, and we’re thrilled to back Aisel as they prove both to change one of the biggest challenges of their generation.”
Amol Sarva, Managing Partner At LifeX Ventures
